Nuvalent is a biotech company creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.
For more details on financing and valuation for Nuvalent, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
NUVL
27.87 as of 3/23/23
To read this article and more news on Nuvalent, register or login.
